March 13 (Reuters) - Pulmatrix Inc:
* PULMATRIX REPORTS 2017 FINANCIAL RESULTS; PROVIDES 2018 OUTLOOK ON PULMONARY DISEASE PIPELINE
* PULMATRIX INC - PHASE 2A STUDY EXPECTED TO BEGIN IN Q4-2018 FOR PULMAZOLE
* PULMATRIX INC - EXPECT NON-CLINICAL SAFETY DATA ON PUR1800 IN SECOND HALF OF 2018
* PULMATRIX INC - FY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.93 Source text for Eikon: Further company coverage: